The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1350
November 1, 2010
View Complete Issue         Table of Contents 2019 
Desirudin (Iprivask) for DVT Prevention
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Desirudin (Iprivask) for DVT Prevention
November 1, 2010 (Issue: 1350)
The injectable direct thrombin inhibitor desirudin (Iprivask – Canyon), a recombinant analog of hirudin, the leech anticoagulant protein, was approved by the FDA in 2003 for prevention of venous thromboembolism (VTE) after elective hip...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Desirudin (Iprivask) for DVT Prevention
Article code: 1350a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.